Brentuximab’s significant effect on apoptotic markers, like Caspase-3 and BAX, across multiple cell lines further confirms its role in inducing cell death through intrinsic apoptotic pathways, especially in aggressive cancers like MDA-MB-231 and U-937. This evidence concerns the gene CASP3 and cancer.